

# Angel Luis Montejo-Gonzalez

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9280179/angel-luis-montejo-gonzalez-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77  
papers

2,578  
citations

28  
h-index

50  
g-index

96  
ext. papers

3,057  
ext. citations

3.8  
avg, IF

5  
L-index

| #  | Paper  | IF   | Citations |
|----|--|------|-----------|
| 77 | Management Strategies for Antipsychotic-Related Sexual Dysfunction: A Clinical Approach. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,   | 5.1  | 4         |
| 76 | Sexuality, Quality of Life, Anxiety, Depression, and Anger in Patients with Anal Fissure. A Case-Control Study. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,  | 5.1  | 1         |
| 75 | The response of the mental health network of the Salamanca area to the COVID-19 pandemic: The role of the telemedicine. <i>Psychiatry Research</i> , <b>2020</b> , 291, 113252   | 9.9  | 28        |
| 74 | Pornography Use in Adolescents and Its Clinical Implications. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,   | 5.1  | 8         |
| 73 | Consensus on Recommendations for Safe Sexual Activity during the COVID-19 Coronavirus Pandemic. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,   | 5.1  | 15        |
| 72 | Understanding the Mechanism of Antidepressant-Related Sexual Dysfunction: Inhibition of Tyrosine Hydroxylase in Dopaminergic Neurons after Treatment with Paroxetine but Not with Agomelatine in Male Rats. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8, | 5.1  | 8         |
| 71 | Frequency of Sexual Dysfunction in Patients Treated with Desvenlafaxine: A Prospective Naturalistic Study. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,  | 5.1  | 4         |
| 70 | Sexual Dysfunction and Quality of Life in Chronic Heroin-Dependent Individuals on Methadone Maintenance Treatment. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,  | 5.1  | 9         |
| 69 | Tardive Dyskinesia After Aripiprazole Treatment That Improved With Tetrabenazine, Clozapine, and Botulinum Toxin. <i>Frontiers in Pharmacology</i> , <b>2019</b> , 10, 281   | 5.6  | 6         |
| 68 | A Real-World Study on Antidepressant-Associated Sexual Dysfunction in 2144 Outpatients: The SALSEX I Study. <i>Archives of Sexual Behavior</i> , <b>2019</b> , 48, 923-933   | 3.5  | 24        |
| 67 | Hormonal Contraceptives, Female Sexual Dysfunction, and Managing Strategies: A Review. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,  | 5.1  | 18        |
| 66 | Management Strategies for Antidepressant-Related Sexual Dysfunction: A Clinical Approach. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,   | 5.1  | 27        |
| 65 | Online Porn Addiction: What We Know and What We Don't-A Systematic Review. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,  | 5.1  | 74        |
| 64 | The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management. <i>World Psychiatry</i> , <b>2018</b> , 17, 3-11   | 14.4 | 65        |
| 63 | Clinically significant personality traits in individuals at high risk of developing psychosis. <i>Psychiatry Research</i> , <b>2018</b> , 261, 498-503   | 9.9  | 10        |
| 62 | Influence of Personality Traits on the Severity of Alcohol Use Disorders. <i>Journal of Clinical Medicine</i> , <b>2018</b> , 7,   | 5.1  | 4         |
| 61 | Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. <i>Frontiers in Neuroendocrinology</i> , <b>2017</b> , 45, 25-34   | 8.9  | 30        |

|    |  |     |    |
|----|--|-----|----|
| 60 | Usefulness of the CAPE-P15 for detecting people at ultra-high risk for psychosis: Psychometric properties and cut-off values. <i>Schizophrenia Research</i> , <b>2017</b> , 189, 69-74   | 3.6 | 28 |
| 59 | Sexual disorders beyond DSM-5: the unfinished affaire. <i>Current Opinion in Psychiatry</i> , <b>2017</b> , 30, 417-422  | 4.9 | 5  |
| 58 | Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia. <i>Revista De Psiquiatría Y Salud Mental</i> , <b>2016</b> , 9, 158-73   | 2.7 | 33 |
| 57 | Sexual behaviour and risk of sexually transmitted infections in young female healthcare students in Spain. <i>PeerJ</i> , <b>2016</b> , 4, e1699   | 3.1 | 4  |
| 56 | Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , <b>2016</b> , 9, 158-173  | 0.2 | 6  |
| 55 | Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale. <i>Journal of Psychopharmacology</i> , <b>2015</b> , 29, 1119-28                     | 4.6 | 21 |
| 54 | Sexual quality of life in gender-dysphoric adults before genital sex reassignment surgery. <i>Journal of Sexual Medicine</i> , <b>2015</b> , 12, 180-8   | 1.1 | 35 |
| 53 | Sexual side-effects of antidepressant and antipsychotic drugs. <i>Current Opinion in Psychiatry</i> , <b>2015</b> , 28, 418-23   | 4.9 | 86 |
| 52 | E.02.02 Sexual side effects of antipsychotics. <i>European Neuropsychopharmacology</i> , <b>2014</b> , 24, S148  | 1.2 |    |
| 51 | Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial. <i>International Journal of Geriatric Psychiatry</i> , <b>2014</b> , 29, 978-86                | 3.9 | 21 |
| 50 | Systematic depression screening in high-risk patients attending primary care: a pragmatic cluster-randomized trial. <i>BMC Psychiatry</i> , <b>2013</b> , 13, 83   | 4.2 | 14 |
| 49 | Sexuality and obsessive-compulsive disorder: the hidden affair. <i>Neuropsychiatry</i> , <b>2013</b> , 3, 23-31  | 1.8 | 13 |
| 48 | Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: results from the CLAMORS study. <i>European Psychiatry</i> , <b>2012</b> , 27, 267-74  | 6   | 15 |
| 47 | Ziprasidone versus Olanzapine in the weight gain associated with the treatment of schizophrenia: A six-month double-blind randomized parallel group study. <i>European Journal of Psychiatry</i> , <b>2012</b> , 26, 248-259                                       | 2.5 | 4  |
| 46 | Delphi consensus on the physical health of patients with schizophrenia: evaluation of the recommendations of the Spanish Societies of Psychiatry and Biological Psychiatry by a panel of experts. <i>Actas Espanolas De Psiquiatria</i> , <b>2012</b> , 40, 114-28 | 0.7 | 8  |
| 45 | Estimation of a multiattribute utility function for the Spanish version of the Tool questionnaire. <i>Value in Health</i> , <b>2011</b> , 14, 564-70   | 3.3 | 7  |
| 44 | Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder. <i>Journal of Sexual Medicine</i> , <b>2011</b> , 8, 773-82  | 1.1 | 19 |
| 43 | Functional impairment related to painful physical symptoms in patients with generalized anxiety disorder with or without comorbid major depressive disorder: post hoc analysis of a cross-sectional study. <i>BMC Psychiatry</i> , <b>2011</b> , 11, 69            | 4.2 | 8  |

|    |   |     |     |
|----|---|-----|-----|
| 42 | Validation of a specific measure to assess health-related quality of life in patients with schizophrenia and bipolar disorder: the Tolerability and quality of life (TOOL) questionnaire. <i>Annals of General Psychiatry</i> , <b>2011</b> , 10, 6   | 3.4 | 7   |
| 41 | The effects of agomelatine on sexual function in depressed patients and healthy volunteers. <i>Human Psychopharmacology</i> , <b>2011</b> , 26, 537-42  | 2.3 | 38  |
| 40 | Treatment-emergent sexual dysfunction with SSRIs and duloxetine: effectiveness and functional outcomes over a 6-month observational period. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2011</b> , 15, 242-54  | 2.4 | 27  |
| 39 | Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. <i>Journal of Psychopharmacology</i> , <b>2010</b> , 24, 111-20                                    | 4.6 | 76  |
| 38 | The need for routine physical health care in schizophrenia. <i>European Psychiatry</i> , <b>2010</b> , 25 Suppl 2, S3-5   | 6   | 33  |
| 37 | Management of physical health in patients with schizophrenia: practical recommendations. <i>European Psychiatry</i> , <b>2010</b> , 25 Suppl 2, S41-5   | 6   | 26  |
| 36 | Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, 109-20 | 4.6 | 179 |
| 35 | Presence and predictors of pain in depression: results from the FINDER study. <i>Journal of Affective Disorders</i> , <b>2010</b> , 125, 53-60  | 6.6 | 36  |
| 34 | Generalized anxiety disorder, with or without co-morbid major depressive disorder, in primary care: prevalence of painful somatic symptoms, functioning and health status. <i>Journal of Affective Disorders</i> , <b>2010</b> , 127, 160-8   | 6.6 | 39  |
| 33 | Sexual function in chronic illness. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 374-88   | 1.1 | 148 |
| 32 | Frequency of sexual dysfunction in patients with a psychotic disorder receiving antipsychotics. <i>Journal of Sexual Medicine</i> , <b>2010</b> , 7, 3404-13  | 1.1 | 70  |
| 31 | Switching to duloxetine in selective serotonin reuptake inhibitor non- and partial-responders: effects on painful physical symptoms of depression. <i>Journal of Psychiatric Research</i> , <b>2009</b> , 43, 512-8   | 5.2 | 38  |
| 30 | Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER. <i>Journal of Affective Disorders</i> , <b>2009</b> , 113, 296-302   | 6.6 | 44  |
| 29 | The socioeconomic costs of mental illness in Spain. <i>European Journal of Health Economics</i> , <b>2009</b> , 10, 361-9   | 6   | 33  |
| 28 | Análisis farmacoeconómico del cambio de tratamiento antipsicótico, por ineficacia o efectos adversos, a quetiapina de liberación prolongada. <i>Pharmacoeconomics - Spanish Research Articles</i> , <b>2009</b> , 6, 105-114  |     | 1   |
| 27 | P.3.c.060 Changes in hyperprolactinaemia and related adverse events after switching antipsychotic treatment to quetiapine. <i>European Neuropsychopharmacology</i> , <b>2009</b> , 19, S544-S545  | 1.2 | 0   |
| 26 | PMH62 THE SPANISH VERSION OF THE TOOL QUESTIONNAIRE: VALIDATION OF A SPECIFIC MEASURE TO EVALUATE HEALTH RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER. <i>Value in Health</i> , <b>2009</b> , 12, A362   | 3.3 | 2   |
| 25 | Toward depression remission: balancing efficacy and tolerability. <i>Journal of Clinical Psychiatry</i> , <b>2009</b> , 70, e36   | 4.6 | 1   |

|    |  |     |     |
|----|--|-----|-----|
| 24 | "Caseness" for depression and anxiety in a depressed outpatient population: symptomatic outcome as a function of baseline diagnostic categories. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , <b>2009</b> , 11, 307-15                                  |     | 19  |
| 23 | PMH43 THE SPANISH VERSION OF THE TOOL QUESTIONNAIRE: A USEFUL MEASURE FOR EVALUATING THE HRQOL AND UTILITIES FROM SCHIZOPHRENIC AND BIPOLAR PATIENTS. <i>Value in Health</i> , <b>2008</b> , 11, A593  | 3.3 | 2   |
| 22 | Physical health considerations in psychiatry: european views on recognition, monitoring and management. <i>European Neuropsychopharmacology</i> , <b>2008</b> , 18 Suppl 2, iii  | 1.2 | 2   |
| 21 | Prolactin awareness: an essential consideration for physical health in schizophrenia. <i>European Neuropsychopharmacology</i> , <b>2008</b> , 18 Suppl 2, S108-14  | 1.2 | 46  |
| 20 | Factors influencing depression endpoints research (FINDER): study design and population characteristics. <i>European Psychiatry</i> , <b>2008</b> , 23, 57-65  | 6   | 20  |
| 19 | Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. <i>European Psychiatry</i> , <b>2008</b> , 23, 66-73   | 6   | 128 |
| 18 | Psychometric properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in patients with schizophrenia and other psychotic disorders. <i>Journal of Sex and Marital Therapy</i> , <b>2008</b> , 34, 227-39   | 2.7 | 66  |
| 17 | Changes in sexual function for outpatients with schizophrenia or other psychotic disorders treated with ziprasidone in clinical practice settings: a 3-month prospective, observational study. <i>Journal of Clinical Psychopharmacology</i> , <b>2008</b> , 28, 568-70          | 1.7 | 31  |
| 16 | Modelos de prescripci3n de antidepressivos en Europa: Resultados del estudio de los Factores que Influyen en la Investigaci3n de los Criterios de Valoraci3n de la Depresi3n (FINDER). <i>European Psychiatry (Ed Espa3ola)</i> , <b>2008</b> , 15, 167-175                      |     |     |
| 15 | Factores que influyen en la investigaci3n de los criterios de valoraci3n de la depresi3n (FINDER): Dise3n del estudio y caracter3sticas de la poblaci3n. <i>European Psychiatry (Ed Espa3ola)</i> , <b>2008</b> , 15, 187-196  |     |     |
| 14 | The "Seroquel" Outcomes Study (SOS): Efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia. <i>International Journal of Psychiatry in Clinical Practice</i> , <b>2007</b> , 11, 222-32                                       | 2.4 |     |
| 13 | P.2.c.015 Better sexual acceptability of agomelatine compared to paroxetine in healthy male volunteers using the PRSexDQ Scale. <i>European Neuropsychopharmacology</i> , <b>2007</b> , 17, S349   | 1.2 | 6   |
| 12 | Duloxetine in the prevention of relapse of major depressive disorder: double-blind placebo-controlled study. <i>British Journal of Psychiatry</i> , <b>2006</b> , 188, 346-53  | 5.4 | 67  |
| 11 | Subjective perception of cognitive deficit in psychotic patients. <i>Journal of Nervous and Mental Disease</i> , <b>2006</b> , 194, 58-60  | 1.8 | 11  |
| 10 | The costs of schizophrenia in Spain. <i>European Journal of Health Economics</i> , <b>2006</b> , 7, 182-88   | 3.6 | 39  |
| 9  | Major depressive disorder, antidepressants, and sexual dysfunction. <i>Journal of Clinical Psychiatry</i> , <b>2006</b> , 67 Suppl 6, 33-7   | 4.6 | 26  |
| 8  | Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>2005</b> , 29, 972-82 | 5.5 | 23  |
| 7  | A 6-month prospective observational study on the effects of quetiapine on sexual functioning. <i>Journal of Clinical Psychopharmacology</i> , <b>2005</b> , 25, 533-8  | 1.7 | 34  |

|   |   |     |     |
|---|---|-----|-----|
| 6 | Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. <i>Schizophrenia Research</i> , <b>2003</b> , 62, 77-88  | 3.6 | 95  |
| 5 | Fluoxetine in the prevention of depressive recurrences: a double-blind study. <i>Journal of Clinical Psychopharmacology</i> , <b>2001</b> , 21, 417-24  | 1.7 | 35  |
| 4 | Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. EFESO Study Group. Estudio Farmacoepidemiologico en la Esquizofrenia con Olanzapina. <i>Clinical Therapeutics</i> , <b>2000</b> , 22, 583-99 | 3.5 | 44  |
| 3 | SSRI antidepressant use patterns and their relation to clinical global impression scores: a naturalistic study. <i>Journal of Affective Disorders</i> , <b>1999</b> , 52, 111-9   | 6.6 | 6   |
| 2 | SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. <i>Journal of Sex and Marital Therapy</i> , <b>1997</b> , 23, 176-94  | 2.7 | 405 |
| 1 | Aggression and depression. <i>European Neuropsychopharmacology</i> , <b>1992</b> , 2, 214-215   | 1.2 |     |